Modifiable environmental factors in multiple sclerosis;Fatores ambientais modificáveis na esclerose múltipla

Arquivos de Neuro-Psiquiatria

Volumn 72, Issue 11, 2014, Pages 889-894

  Fragoso, Yara Dadalti ^a  

^a UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

Author keywords

Exercise; Multiple sclerosis; Obesity; Smoking; Vitamin A; Vitamin D

Indexed keywords

ALCOHOL; C REACTIVE PROTEIN; CAROTENOID; GAMMA INTERFERON; INTERLEUKIN 12; LEPTIN; MATRIX METALLOPROTEINASE; OMEGA 3 FATTY ACID; PROBIOTIC AGENT; RETINOL; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC INFLAMMATION; ENVIRONMENTAL FACTOR; EXERCISE; HUMAN; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; OBESITY; PHYSICAL ACTIVITY; REVIEW; SALT INTAKE; SEDENTARY LIFESTYLE; SMOKING; TOBACCO CONSUMPTION; COMPLICATION; ENVIRONMENT; RETINOL DEFICIENCY; RISK FACTOR; VITAMIN D DEFICIENCY;

ENVIRONMENT; HUMANS; MULTIPLE SCLEROSIS; OBESITY; RISK FACTORS; SEDENTARY LIFESTYLE; SMOKING; VITAMIN A DEFICIENCY; VITAMIN D DEFICIENCY;

EID: 84911360224     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282X20140159     Document Type: Review

References (62)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000; 343(13): 938-52. http://dx. doi. org/10. 1056/nejm200009283431307.
2. Fragoso YD, Arruda NM, Arruda WO, Brooks JBB, Correa EC, Damasceno A et al. We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it? Expert Rev Neurother. 2014; 14(2): 127-30. http://dx. doi. org/10. 1586/14737175. 2014. 874947.
3. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics. 2013; 10(1): 2-18. http://dx. doi. org/10. 1007/s13311-012-0163-4.
4. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009; 277 Suppl 1: S42-5. http://dx. doi. org/10. 1007/s13311-012-0163-4.
5. Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006; 15(11): 737-45. http://dx. doi. org/10. 1177/0961203306069344.
6. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Moradi V, Nonhal S, Ghorbani A et al. Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran. Neuroepidemiology. 2011; 37(3-4): 238-42. http://dx. doi. org/10. 1159/000332765.
7. Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest. 2001; 31(6): 550-3. http://dx. doi. org/10. 1046/j. 1365-2362. 2001. 00842. x.
8. Wang F, Lu Z, Hawkes M, Yang H, Kain KC, Liles WC. Fas (CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from macrophages. J Inflamm (Lond). 2010; 7(1): 30. http://dx. doi. org/10. 1186/1476-9255-7-30.
9. Seagrave J, Barr EB, March TH, Nikula KJ. Effects of cigarette smoke exposure and cessation on inflammatory cells and matrix metalloproteinase activity in mice. Exp Lung Res. 2004; 30(1): 1-15. http://dx. doi. org/10. 1080/01902140490252858.
10. Moszczyński P, Żabiński Z, Moszczyński P Jr, Rutowski J, Słowińskia S, Tabarowski Z. Immunological findings in cigarette smokers. Toxicol Lett. 2001; 118(3): 121-7. http://dx. doi. org/10. 1016/s0378-4274(00)00270-8.
11. Robbins CS, Dawe DE, Goncharova SI, Pouladi MA, Drannik AG, Swirski FK et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol. 2004; 30(2): 202-11. http://dx. doi. org/10. 1165/rcmb. 2003-0259oc.
12. Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013; 136(Pt 7): 2298-304. http://dx. doi. org/10. 1093/brain/awt139.
13. Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of secondary progressive multiple sclerosis: A study in IRAN, Guilan. J Neurol Sci. 2013; 330(1-2): 52-5. http://dx. doi. org/10. 1016/j. jns. 2013. 04. 003.
14. Hedström A, Alfredsson L, Lundkvist Ryner M, Fogdell-Hahn A, Hillert J, Olsson T. Smokers run increased risk of developing antinatalizumab antibodies. Mult Scler. 2013; 20(8): 1081-5. http://dx. doi. org/10. 1177/1352458513515086.
15. O'Gorman C, Broadley SA. Smoking and multiple sclerosis: evidence for latitudinal and temporal variation. J Neurol. 2014; 261(9)1677-83. http://dx. doi. org/10. 1007/s00415-014-7397-5.
16. Briggs FB, Acuna B, Shen L, Ramsay P, Quach H, Bernstein A et al. Smoking and risk of multiple sclerosis: evidence of modification by NAT1 variants. Epidemiology. 2014; 25(4): 605-14. http://dx. doi. org/10. 1097/ede. 0000000000000089.
17. Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler. 2011; 17(7): 788-93. http://dx. doi. org/10. 1177/1352458511399610.
18. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009; 73(19): 1543-50. http://dx. doi. org/10. 1212/wnl. 0b013e3181c0d6e0.
19. Munger K, Bentzen J, Laursen B, Stenager E, Koch-Henrisken N, Sørensen TI et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler, 2013; 19(10): 1323-9. http://dx. doi. org/10. 1177/1352458513483889.
20. Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler. 2012; 18(9): 1334-6. http://dx. doi. org/10. 1177/1352458512436596.
21. Harpsøe MC, Basit S, Andersson M, Nielsen NM, Frisch M, Wohlfahrt J et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol. 2014; 43(3): 843-55. http://dx. doi. org/10. 1093/ije/dyu045.
22. Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleinewietfeld M. Role of "western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014; 14(1): 404. http://dx. doi. org/10. 1007/s11882-013-0404-6.
23. Fietta P, Delsante G. Focus on adipokines. Theor Biol Forum. 2013; 106(1-2): 103-29.
24. Ouchi N, Ohashi K, Shibata R, Murohara T. Adipocytokines and obesity-linked disorders. Nagoya J Med Sci. 2012; 74(1-2): 19-30.
25. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008; 133(5): 775-87. http://dx. doi. org/10. 1016/j. cell. 2008. 05. 009.
26. Zeng H, Chi H. The interplay between regulatory T cells and metabolism in immune regulation. Oncoimmunology. 2013; 2(11): e26586. http://dx. doi. org/10. 4161/onci. 26586.
27. De Rosa V, Procaccini C, Calì G, Pirozzi G, Fontana S, Zappacosta S et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007; 26(2): 241-55. http://dx. doi. org/10. 1016/j. immuni. 2007. 01. 011.
28. Wagner NM, Brandhorst G, Czepluch F, Lankeit M, Eberl C, Herzberg S et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring). 2013; 21(3): 461-8. http://dx. doi. org/10. 1002/oby. 20087.
29. Deng J, Liu Y, Yang M, Wang Z, Zhang M, Wang X et al. Leptin exacerbates collagen-induced arthritis via enhancement of Th17 cell response. Arthritis Rheum. 2012; 64(11): 3564-73. http://dx. doi. org/10. 1002/art. 34637.
30. Yu Y, Liu Y, Shi FD, Zou H, Matarese G, La Cava A. Cutting edge: Leptin-induced RORct expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol. 2013; 190(7): 3054-8. http://dx. doi. org/10. 4049/jimmunol. 1203275.
31. Pucino V, De Rosa V, Procaccini C, Matarese G. Regulatory T cells, leptin and angiogenesis. Chem Immunol Allergy. 2014; 99: 155-69. http://dx. doi. org/10. 1159/000353557.
32. Fragoso YD, Stoney PN, McCaffery PJ. The evidence for a beneficial role of vitamin A in multiple sclerosis. CNS Drugs. 2014; 28(4): 291-9. http://dx. doi. org/10. 1007/s40263-014-0148-4.
33. Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity. 2011; 35(1): 13-22. http://dx. doi. org/10. 1016/j. immuni. 2011. 07. 002.
34. Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011; 14(1): 45-53. http://dx. doi. org/10. 1038/nn. 2702.
35. Massacesi L, Castigli E, Vergelli M, Olivotto J, Abbamondi AL, Sarlo F et al. Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. J Clin Invest. 1991; 88(4): 1331-7. http://dx. doi. org/10. 1172/JCI115438.
36. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol. 1995; 154(1): 450-8.
37. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008; 194(1-2): 7-17. http://dx. doi. org/10. 1016/j. jneuroim. 2007. 11. 014.
38. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1a, 25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 2001; 167(9): 4974-80. http://dx. doi. org/10. 4049/jimmunol. 167. 9. 4974.
39. Korf H, Wenes M, Stijelmans B, Takiishi T, Robert S, Miani M et al. 1, 25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology. 2012; 217(12): 1292-300. http://dx. doi. org/10. 1016/j. imbio. 2012. 07. 018.
40. Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014; 71(3): 306-14. http://dx. doi. org/10. 1001/jamaneurol. 2013. 5993.
41. Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add-on treatment to interferon b-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatr. 2012; 83(5): 565-71. http://dx. doi. org/10. 1136/jnnp-2011-301876.
42. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 2012; 12(2): 127-36. http://dx. doi. org/10. 1016/j. autrev. 2012. 07. 007.
43. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014; 348: g2035. http://dx. doi. org/10. 1136/bmj. g2035.
44. Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol. 2012; 25(3): 246-51. http://dx. doi. org/10. 1097/WCO. 0b013e3283533a7e.
45. Ikeda U, Wakita D, Ohkuri T, Chamoto K, Kitamura H, Iwakura Y et al. 1alpha, 25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett. 2010; 134(1): 7-16. http://dx. doi. org/10. 1016/j. imlet. 2010. 07. 002.
46. Sá MJ. Exercise therapy and multiple sclerosis: a systematic review. J Neurol. 2013; 261(9)1651-61. http://dx. doi. org/10. 1007/s00415-013-7183-9.
47. Golzari Z, Shabkhiz F, Soudi S, Kordi MR, Hashemi SM. Combined exercise training reduces IFN-c and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol. 2010; 10(11): 1415-9. http://dx. doi. org/10. 1016/j. intimp. 2010. 08. 008.
48. Swank C, Thompson M, Medley A. Aerobic exercise in people with multiple sclerosis: its feasibility and secondary benefits. Int J MS Care. 2013; 15(3): 138-45. http://dx. doi. org/10. 7224/1537-2073. 2012-037.
49. Dinas PC, Koutedakis Y, Flouris AD. Effects of exercise and physical activity on depression. Ir J Med Sci. 2011; 180(2): 319-25. http://dx. doi. org/10. 1007/s11845-010-0633-9.
50. Kleinewietfeld M, Manzel A, Titze J, Kvazan H, Yosef N, Linker RA et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013; 496(7446): 518-22. http://dx. doi. org/10. 1038/nature11868.
51. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013; 496(7446): 513-7. http://dx. doi. org/10. 1038/nature11984.
52. Issazadeh-Navikas S, Teimer R, Bockermann R. Influence of dietary components on regulatory T cells. Mol Med. 2012; 18(1): 95-110. http://dx. doi. org/10. 2119/molmed. 2011. 00311.
53. Kim W, Lee H. Advances in nutritional research on regulatory T-cells. Nutrients. 2013; 5(11): 4305-15. http://dx. doi. org/10. 3390/nu5114305.
54. Hedström AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol. 2014; 71(3): 300-5. http://dx. doi. org/10. 1001/jamaneurol. 2013. 5858.
55. Beier M, D'Orio V, Spat J, Shuman M, Foley FW. Alcohol and substance use in multiple sclerosis. J Neurol Sci. 2014; 338(1-2): 122-7. http://dx. doi. org/10. 1016/j. jns. 2013. 12. 029.
56. Freysdottir J, Sigurpalsson MB, Omarsdottir S, Olafsdottir ES, Vikingsson A, Hardardottir I. Ethanol extract from birch bark (Betula pubescens) suppresses human dendritic cell mediated Th1 responses and directs it towards a Th17 regulatory response in vitro. Immunol Lett. 2011; 136(1): 90-6. http://dx. doi. org/10. 1016/j. imlet. 2010. 12. 009.
57. Kachuck NJ. When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis. Neuropsychiatr Dis Treat. 2011; 7: 197-208. http://dx. doi. org/10. 2147/NDT. S17522.
58. Heesen C, Kleiter I, Nguyen F, Schäffler N, Kwasper J, Köpke S, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler. 2010; 16(12): 1507-12. http://dx. doi. org/10. 1177/1352458510379819.
59. Valdueza JM, Doepp F, Schreiber SJ, Oosten BW, Schmierer K, Paul F et al. What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab. 2013; 33(5): 657-68. http://dx. doi. org/10. 1038/jcbfm. 2013. 31.
60. Pekmezovic T, Drulovic J, Milenkovic M, Jarebinski M, Stojsavljevic N, Mesaros S et al. Lifestyle factors and multiple sclerosis: a casecontrol study in Belgrade. Neuroepidemiology. 2006; 27(4): 212-6. http://dx. doi. org/10. 1159/000096853.
61. Salzer J, Biström M, Sundström P. Vitamin D and multiple sclerosis: where do we go from here? Expert Rev Neurother. 2014; 14(1): 9-18. http://dx. doi. org/10. 1586/14737175. 2014. 864952.
62. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci. 2011; 305(1-2): 1-10. http://dx. doi. org/10. 1016/j. jns. 2011. 03. 026.